Drug updated on 5/1/2024
Dosage Form | Tablet (oral; 5 mg, 7.5 mg); Solution (oral; 5 mg/5 mL [1 mg/mL]) |
Drug Class | Hyperpolarization-activated cyclic nucleotide-gated channel blockers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
- Indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
Summary
- Ivabradine (Corlanor) is indicated for reducing the risk of hospitalization due to worsening heart failure in adult patients with stable, symptomatic chronic heart failure and reduced left ventricular ejection fraction.
- The drug also treats stable symptomatic heart failure caused by dilated cardiomyopathy in pediatric patients aged 6 months and older.
- A review of 23 systematic reviews/meta-analyses shows that ivabradine (Corlanor), when combined with background therapy, significantly reduces hospitalizations for heart failure or cardiovascular death.
- Ivabradine (Corlanor) has been found to improve cardiac function by reducing the heart rate, improving left ventricular ejection fraction, and decreasing left ventricular dimensions.
- In terms of safety profile, ivabradine's use on top of background therapy presents a comparable risk level to those treated solely with background therapy; however it does increase the incidence of atrial fibrillation especially in patients with LVEF >40% as well as visual disturbances and asymptomatic bradycardia among CHF patients compared to placebo or standard care groups.
- Subgroup analysis suggests consistent benefits across various patient subgroups but data on specific populations such as those suffering from HFpEF or advanced NYHA class IV symptoms are limited or inconclusive at this time.
- Compared against other drugs like beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin-converting enzyme inhibitors (ACEIs), ARNIs and SGLT2 inhibitors used for treating HFrEF conditions - while effective - ivabradine may not always feature prominently within most beneficial combinations particularly regarding mortality reduction outcomes where combination therapies involving ARNI’s Beta-blockers MRA’s & SGLT2 inhibitors were found more effective overall.
- Ivabradine improves health-related quality-of-life measures along with New York Heart Association (NYHA) class, indicating its effectiveness in managing symptoms of heart failure.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Corlanor (ivabradine) Prescribing Information. | 2021 | Amgen Inc., Thousand Oaks, CA |